Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ COVID-19 case 63% Improvement Relative Risk HCQ for COVID-19  Ferri et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,641 patients in Italy Fewer cases with HCQ (p=0.015) Ferri et al., Clinical Rheumatology, Aug 2020 Favors HCQ Favors control

COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series

Ferri et al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7
Aug 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ etc.) RR 0.37, p=0.015.
csDMARDs include HCQ, CQ, and several other drugs, so the effect of HCQ/CQ alone could be higher.
This study also confirms that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, OR 4.42, p<0.001 (this is the observed real-world risk which takes into account factors such as these patients potentially being more careful to avoid exposure).
(results are for "definite + highly suspected" cases and the main result is presented in the paper as the OR for not taking csDMARDs, we have converted this to RR for taking csDMARDs).
risk of COVID-19 case, 63.0% lower, RR 0.37, p = 0.01, treatment 9 of 994 (0.9%), control 16 of 647 (2.5%), NNT 64.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ferri et al., 27 Aug 2020, retrospective, Italy, peer-reviewed, survey, 29 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Massimo L’andolina, Antonio Tavoni, Riccardo Cecchetti, Serena Guiducci, Francesco Ursini, Maurizio Caminiti, Giuseppe Varcasia, Pietro Gigliotti, Roberta Pellegrini, Domenico Olivo, Michele Colaci, Giuseppe Murdaca, Raffaele Brittelli, Giuseppa Pagano Mariano, Amelia Spinella, Silvia Bellando-Randone, Vincenzo Aiello, Silvia Bilia, Daiana Giannini, Tommaso Ferrari, Rodolfo Caminiti, Veronica Brusi, Riccardo Meliconi, Poupak Fallahi, Alessandro Antonelli
Clinical Rheumatology, doi:10.1007/s10067-020-05334-7
Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease, or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to "Italian general population" (p = .030, p = .001, p = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions (p = .000, for all comparisons with the respective regional general population). Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various "connective tissue diseases" compared to "inflammatory arthritis group" (p < .000), or in
Antonelli, Elia, Ferrari, Foddis, Marco et al., The Covid-19, epidemiology, Clinic and Prevention, Curr Genomics, doi:10.2174/1389202921999200427133052
Beydon, Chevalier, Tabaa, Hamroun, Delettre et al., Myositis as a manifestation of SARS-CoV-2, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217549
Bijlsma, Hachulla, EULAR textbook on rheumatic diseases
Bozzalla Cassione, Zanframundo, Biglia, Codullo, Montecucco et al., COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis annrheumdis, doi:10.1136/annrheumdis-2020-217717
Cheng, Li, Zhao, Yue, Yang et al., COVID-19 with rheumatic diseases: a report of 5 cases, Clin Rheumatol, doi:10.1007/s10067-020-05160-x
Conticini, Bargagli, Bardelli, Rana, Baldi et al., COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217681
Emmi, Bettiol, Mattioli, Silvestri, Scala et al., SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmunity Rev, doi:10.1016/j.autrev.2020.102575
Favalli, Ingegnoli, Cimaz, Caporali, What is the true incidence of COVID-19 in patients with rheumatic diseases?, Ann Rheum Dis annrheumdis, doi:10.1136/annrheumdis-2020-217615
Ferro, Elefante, Baldini, Bartoloni, Puxeddu et al., COVID-19: the new challenge for rheumatologists, Clin Exp Rheumatol
Gianfrancesco, Hyrich, Gossec, Strangfeld, Carmona et al., Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries, Lancet Rheumatol, doi:10.1016/s2665-9913(20)30095-3
Guan, Ni, Hu, Liang, Ou et al., China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/nejmoa2002032
Guilpain, Bihan, Foulongne, Taourel, Pansu et al., Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217549
Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in immune-mediated inflammatory diseases -case series from New York, N Engl J Med, doi:10.1056/nejmc2009567
Jones, Mills, Suarez, Hogan, Yeh et al., COVID-19 and Kawasaki disease: novel virus and novel case, Hosp Pediatr, doi:10.1542/hpeds.2020-0123
Lake, What we know so far: COVID-19 current clinical knowledge and research, Clin Med (Lond), doi:10.7861/clinmed.2019-coron
Lu, Li, Liu, Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217460
Marotto, Sarzi-Puttini, What is the role of rheumatologists in the era of COVID-19?, Autoimmun Rev, doi:10.1016/j.autrev.2020.102539
Mathian, Mahevas, Rohmer, Roumier, Cohen-Aubart et al., Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566
Matucci-Cerinic, Bruni, Allanore, Clementi, Dagna et al., Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217407
Mcgonagle, Sharif, 'regan, Bridgewood, The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease, Autoimmun Rev, doi:10.1016/j.autrev.2020.102537
Mehta, Ma, Brown, Sanchez, Tattersall et al., HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/s0140-6736(20)30628-0
Memoli, Athota, Reed, Czajkowski, Bristol et al., The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts, Clin Infect Dis, doi:10.1093/cid/cit725
Mihai, Dobrota, Schröder, Garaiman, Jordan et al., 2 COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217442
Monti, Balduzzi, Delvino, Bellis, Quadrelli et al., Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217424
Papa, Sambataro, Minniti, Pignataro, Caporali, Novel COronaVirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients?, Autoimmun Rev, doi:10.1016/j.autrev.2020.102558
Quartuccio, Valent, Pasut, Tascini, Vita, biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy, doi:10.1016/j.jbspin.2020.05.003
Riccardo, Andrianou, Manso, Urdiales, Fabiani, Integrated surveillance of COVID-19 in Italy (Epidemia COVID-19)
Tomelleri, Sartorelli, Campochiaro, Baldissera, Dagna, Impact of COVID-19 pandemic on patients with largevessel vasculitis in Italy: a monocentric survey, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217600
Verdoni, Mazza, Gervasoni, Martelli, Ruggeri et al., An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study, Lancet, doi:10.1016/s0140-6736(20)31103-x
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Who, Coronavirus disease
Xie, Chen, Insight into 2019 novel coronavirus -an updated intrim review and lessons from SARS-CoV and MERS-CoV, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.071
Zen, Fuzzi, Astorri, Saccon, Padoan et al., SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients, J Autoimmun, doi:10.1016/j.jaut.2020.102502
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop